### UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK

|        | • |            |
|--------|---|------------|
|        | • |            |
| In re: | : | Chapter 11 |

PURDUE PHARMA L.P., et al., : Case No. 19-23649 (RDD)

Debtors.<sup>1</sup> : (Jointly Administered)

# SEVENTH MONTHLY FEE STATEMENT OF KPMG LLP FOR COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES INCURRED AS TAX CONSULTANT FOR THE DEBTORS AND THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS FOR THE PERIOD FROM JULY 1, 2020 THROUGH JULY 31, 2020

| Name of Applicant:   | KPMG               | LLP   |
|--|--------------------|---|
| Authorized to Provide Professional Services to:                              |                    | ebtors and the Official Committee of ured Creditors |
| Date of Retention:   |                    | ry 24, 2020, <i>nunc pro tunc</i> to ber 23, 2019   |
| Period for Which Compensation and Reimbursement is Sought:                   | July 1,<br>July 31 | 2020 through , 2020                                 |
| Amount of Compensation Sought as Actual, Reasonable, and Necessary:          | \$                 | 234,078.90  |
| Less 20% Holdback:   | \$                 | (46,815.78)   |
| Amount of Expense Reimbursement Sought as Actual, Reasonable, and Necessary: | \$                 | 0.00  |
| Total Fees and Expenses Due:   | \$                 | 187,263.12  |

The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Dated: September 3, 2020

/s/ Howard Steinberg

Howard Steinberg Partner, KPMG LLP 1350 Avenue of the Americas New York, New York 10019 (212) 872-6562

### **EXHIBIT A**

### Purdue Pharma L.P. Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional July 1, 2020 through July 31, 2020

| Professional Person              | Position & Department                       | Country of<br>Origin | Total<br>Billed Hours | Hou | rly Billing<br>Rate | Co | Total<br>ompensation |
|----------------------------------|---|----------------------|-----------------------|-----|---------------------|----|----------------------|
| Anthony Minervini                | Managing Director - Washington National Tax | US                   | 16.0                  | \$  | 893                 | \$ | 14,288.00            |
| Aroen Rambhadjan                 | Partner - Tax                               | Netherlands          | 1.2                   | \$  | 884                 | \$ | 1,060.80             |
| Ashley Armfield                  | Senior Associate - M&A Tax                  | US                   | 20.9                  | \$  | 534                 | \$ | 11,160.60            |
| Becky Holtje                     | Senior Manager - Washington National Tax    | US                   | 7.0                   | \$  | 744                 | \$ | 5,208.00             |
| Bela Unell                       | Senior Manager - Washington National Tax    | US                   | 3.1                   | \$  | 744                 | \$ | 2,306.40             |
| Carol Conjura                    | Partner - Washington National Tax           | US                   | 0.5                   | \$  | 906                 | \$ | 453.00               |
| Casey Nunez                      | Senior Manager - M&A Tax                    | US                   | 23.6                  | \$  | 744                 | \$ | 17,558.40            |
| Devon Rowles                     | Associate - M&A Tax                         | US                   | 26.0                  | \$  | 350                 | \$ | 9,100.00             |
| Diego Lipp                       | Senior Associate - Tax                      | Switzerland          | 0.6                   | \$  | 430                 | \$ | 258.00               |
| Douglas Holland                  | Principal - Washington National Tax         | US                   | 2.4                   | \$  | 985                 | \$ | 2,364.00             |
| Frankie Angeleri                 | Associate - Economic & Valuation Services   | US                   | 41.6                  | \$  | 520                 | \$ | 21,632.00            |
| Gabriela Baker                   | Senior Associate - International Tax        | US                   | 17.6                  | \$  | 534                 | \$ | 9,398.40             |
| Howard Steinberg                 | Partner - M&A Tax                           | US                   | 8.6                   | \$  | 856                 | \$ | 7,361.60             |
| Isaac Hirsch                     | Managing Director - Int'l Tax               | US                   | 57.9                  | \$  | 819                 | \$ | 47,420.10            |
| Jess Commisso                    | Associate - M&A Tax                         | US                   | 29.9                  | \$  | 350                 | \$ | 10,465.00            |
| Jim Tod                          | Partner - Washington National Tax           | US                   | 4.6                   | \$  | 906                 | \$ | 4,167.60             |
| Jonas Lau                        | Senior Manager - Tax                        | Canada               | 0.4                   | \$  | 614                 | \$ | 245.60               |
| Kieran Taylor                    | Senior Manager - Tax                        | US                   | 6.8                   | \$  | 744                 | \$ | 5,059.20             |
| Lukas van der Veen               | Manager - Tax                               | Netherlands          | 3.6                   | \$  | 565                 | \$ | 2,034.00             |
| Mark Hoffenberg                  | Principal - Washington National Tax         | US                   | 2.3                   | \$  | 980                 | \$ | 2,254.00             |
| Molly Minnear                    | Principal - Economic & Valuation Services   | US                   | 1.7                   | \$  | 868                 | \$ | 1,475.60             |
| Monica Plangman                  | Associate Director - Bankruptcy             | US                   | 4.9                   | \$  | 264                 | \$ | 1,293.60             |
| Pete DiMatteo                    | Manager - Int'l Tax                         | US                   | 46.5                  | \$  | 650                 | \$ | 30,225.00            |
| Rob Keller                       | Managing Director - Washington National Tax | US                   | 13.8                  | \$  | 893                 | \$ | 12,323.40            |
| Teresa Williams                  | Associate - Bankruptcy                      | US                   | 3.1                   | \$  | 140                 | \$ | 434.00               |
| Tracy Stone                      | Principal - Washington National Tax         | US                   | 13.9                  | \$  | 906                 | \$ | 12,593.40            |
| Wendy Shaffer                    | Manager - Bankruptcy                        | US                   | 9.6                   | \$  | 202                 | \$ | 1,939.20             |
| Subtotal of Hours and Dis        | scounted Fees                               |                      | 368.1                 |     |                     | \$ | 234,078.90           |
| <b>Total Discounted Fees</b>     |   |                      |                       |     |                     | \$ | 234,078.90           |
| Out of Pocket Expenses           |   |                      |                       |     |                     | \$ | -                    |
| <b>Total Fees and Out of Poo</b> | <del>-</del>                                |                      |                       |     |                     | \$ | 234,078.90           |
| Less Holdback Adjustment         |   |                      |                       |     |                     | \$ | (46,815.78)          |
| Net Requested Fees & Ou          | t of Pocket Expenses                        |                      |                       |     |                     | \$ | 187,263.12           |
|                                  |   |                      |                       |     |                     |    |                      |

KPMG LLP Monthly Fee Statement Page 1 of 27

**Blended Hourly Rate** 

\$

635.91

## 19-23649-rdd Doc 1655 Filed 09/03/20 Entered 09/03/20 22:40:42 Main Document Pg 4 of 29

#### **EXHIBIT B**

### Purdue Pharma L.P. Case No. 19-23649

Summary of Hours and Discounted Fees Incurred by Category July 1, 2020 through July 31, 2020

| Category                             | Exhibit | Total<br>Billed Hours | Total Fees<br>Requested |
|--------------------------------------|---------|-----------------------|-------------------------|
| Bankruptcy Tax Consulting Services   | C1      | 349.0                 | \$<br>229,296.10        |
| Non -Working Travel Time             | C2      | 0.0                   | \$<br>-                 |
| Retention Services                   | C3      | 0.0                   | \$<br>-                 |
| Fee Application Preparation Services | C4      | 19.1                  | \$<br>4,782.80          |
| Total                                |         | 368.1                 | \$<br>234,078.90        |

KPMG LLP Monthly Fee Statement Page 2 of 27

### Purdue Pharma L.P. Case No. 19-23649

| Name             | Date     | Description   | Hours | Rate   | Amount         |
|------------------|----------|---|-------|--------|----------------|
| Isaac Hirsch     | 07/06/20 | (0.8) Performed Managing Director review of updated Dutch disposition planning deck as of 7/6/2020.   | 0.8   | \$ 819 | \$<br>655.20   |
| Isaac Hirsch     | 07/06/20 | (0.9) Perform international tax Managing Director review of updated information request as of 7/6/2020.   | 0.9   | \$ 819 | \$<br>737.10   |
| Howard Steinberg | 07/06/20 | (1.0) Partner review of client deliverables for updated cash tax model regarding tax analysis of Mundipharma disposition.   | 1.0   | \$ 856 | \$<br>856.00   |
| Jess Commisso    | 07/06/20 | (1.2) Review of most recent documentation provided by client as of 7/6/2020, to determine relevance / distribution to various KPMG project teams - to facilitate tax analysis.                | 1.2   | \$ 350 | \$<br>420.00   |
| Pete DiMatteo    | 07/06/20 | (1.9) Performed International tax manager review and concurrently revised potential Canadian separation transactions to reflect additional US federal income tax considerations.              | 1.9   | \$ 650 | \$<br>1,235.00 |
| Isaac Hirsch     | 07/06/20 | (2.0) Perform Managing Director review of updated Cash Tax Modeling Summary & Sensitivity Analysis as of 7/6/2020.  | 2.0   | \$ 819 | \$<br>1,638.00 |
| Pete DiMatteo    | 07/06/20 | (2.3) Performed International tax manager review and concurrently revised the potential Dutch separation transactions to reflect additional US federal income tax considerations;             | 2.3   | \$ 650 | \$<br>1,495.00 |
| Howard Steinberg | 07/08/20 | (1.2) Performed Partner review of client deliverables regarding tax analysis of Mundipharma disposition.  | 1.2   | \$ 856 | \$<br>1,027.20 |
| Frankie Angeleri | 07/07/20 | (0.3) Meeting with K. Taylor and F. Angeleri (KPMG) to discuss comments and additions to the draft transfer pricing memo.   | 0.3   | \$ 520 | \$<br>156.00   |
| Kieran Taylor    | 07/07/20 | (0.3) Meeting with K. Taylor and F. Angeleri (KPMG) to discuss comments and additions to the draft transfer pricing memo.   | 0.3   | \$ 744 | \$<br>223.20   |
| Casey Nunez      | 07/07/20 | (0.4) Call with J. Dougherty (Haug Partners), M. Hoffenberg, I. Hirsch, and C. Nunez (KPMG) to discuss open KPMG information requests relating to U.S. Independent Associate companies (IAC). | 0.4   | \$ 744 | \$<br>297.60   |
| Isaac Hirsch     | 07/07/20 | (0.4) Call with J. Dougherty (Haug Partners), M. Hoffenberg, I. Hirsch, and C. Nunez (KPMG) to discuss open KPMG information requests relating to U.S. Independent Associate companies (IAC). | 0.4   | \$ 819 | \$<br>327.60   |
| Mark Hoffenberg  | 07/07/20 | (0.4) Call with J. Dougherty (Haug Partners), M. Hoffenberg, I. Hirsch, and C. Nunez (KPMG) to discuss open KPMG information requests relating to U.S. Independent Associate companies (IAC). | 0.4   | \$ 980 | \$<br>392.00   |
| Howard Steinberg | 07/07/20 | (0.5) Performed Partner review of updated client deliverables regarding tax analysis of Mundipharma disposition.  | 0.5   | \$ 856 | \$<br>428.00   |
| Frankie Angeleri | 07/07/20 | (0.6) Continued, from earlier in the day, to address review comments on transfer pricing memo while concurrently adding more details related to Purdue business and transfer pricing policies | 0.6   | \$ 520 | \$<br>312.00   |
| Pete DiMatteo    | 07/07/20 | (1.2) Performed additional international tax manager review of updated version of slide deck depicting potential Dutch separation transactions and concurrently drafted review comments.      | 1.2   | \$ 650 | \$<br>780.00   |

### Purdue Pharma L.P. Case No. 19-23649

| Name             | Date     | Description  | Hours | Rate   | Amount         |
|------------------|----------|--|-------|--------|----------------|
| Isaac Hirsch     | 07/07/20 | (1.2) Prepare for call with Haug Partners by reviewing latest version of information request list.   | 1.2   | \$ 819 | \$<br>982.80   |
| Jess Commisso    | 07/07/20 | (1.4) Review of most recent documentation provided by client as of 7/7/2020, to determine relevance (and distribution of same) to various KPMG project teams - to facilitate tax analysis.   | 1.4   | \$ 350 | \$<br>490.00   |
| Pete DiMatteo    | 07/07/20 | (1.6) Perform additional International tax manager review of and concurrently revised updated version of slide deck depicting potential Canadian separation transactions;  | 1.6   | \$ 650 | \$<br>1,040.00 |
| Frankie Angeleri | 07/07/20 | (3.9) Addressed review comments from K. Taylor (KPMG) related to transfer pricing memo.  | 3.9   | \$ 520 | \$<br>2,028.00 |
| Diego Lipp       | 07/08/20 | Drafted email D. Rowles (KPMG US) regarding new Swiss documents uploaded to the virtual data room.   | 0.3   | \$ 430 | \$<br>129.00   |
| Ashley Armfield  | 07/08/20 | (0.3) Discussion with M. Hoffenberg, H. Steinberg, B. Unell, D. Holland, I. Hirsch, C. Nunez, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding circulation of updated client deliverable and next steps related to overall engagement as of 7/8/2020. | 0.3   | \$ 534 | \$<br>160.20   |
| Douglas Holland  | 07/08/20 | (0.3) Discussion with M. Hoffenberg, H. Steinberg, B. Unell, D. Holland, I. Hirsch, C. Nunez, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding circulation of updated client deliverable and next steps related to overall engagement as of 7/8/2020. | 0.3   | \$ 985 | \$<br>295.50   |
| Bela Unell       | 07/08/20 | (0.3) Discussion with M. Hoffenberg, H. Steinberg, B. Unell, D. Holland, I. Hirsch, C. Nunez, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding circulation of updated client deliverable and next steps related to overall engagement as of 7/8/2020. | 0.3   | \$ 744 | \$<br>223.20   |
| Jess Commisso    | 07/08/20 | (0.3) Discussion with M. Hoffenberg, H. Steinberg, B. Unell, D. Holland, I. Hirsch, C. Nunez, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding circulation of updated client deliverable and next steps related to overall engagement as of 7/8/2020. | 0.3   | \$ 350 | \$<br>105.00   |
| Casey Nunez      | 07/08/20 | (0.3) Discussion with M. Hoffenberg, H. Steinberg, B. Unell, D. Holland, I. Hirsch, C. Nunez, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding circulation of updated client deliverable and next steps related to overall engagement as of 7/8/2020. | 0.3   | \$ 744 | \$<br>223.20   |
| Howard Steinberg | 07/08/20 | (0.3) Discussion with M. Hoffenberg, H. Steinberg, B. Unell, D. Holland, I. Hirsch, C. Nunez, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding circulation of updated client deliverable and next steps related to overall engagement as of 7/8/2020. | 0.3   | \$ 856 | \$<br>256.80   |
| Mark Hoffenberg  | 07/08/20 | (0.3) Discussion with M. Hoffenberg, H. Steinberg, B. Unell, D. Holland, I. Hirsch, C. Nunez, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding circulation of updated client deliverable and next steps related to overall engagement as of 7/8/2020. | 0.3   | \$ 980 | \$<br>294.00   |

### Purdue Pharma L.P. Case No. 19-23649

| Name             | Date     | Description  | Hours | Rate   | Amount         |
|------------------|----------|--|-------|--------|----------------|
| Isaac Hirsch     | 07/07/20 | (0.3) Discussion with M. Hoffenberg, H. Steinberg, B. Unell, D. Holland, I. Hirsch, C. Nunez, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding circulation of updated client deliverable and next steps related to overall engagement as of 7/8/2020. | 0.3   | \$ 819 | \$<br>245.70   |
| Devon Rowles     | 07/08/20 | (0.3) Discussion with M. Hoffenberg, H. Steinberg, B. Unell, D. Holland, I. Hirsch, C. Nunez, A. Armfield, D. Rowles and J. Commisso (KPMG) regarding circulation of updated client deliverable and next steps related to overall engagement as of 7/8/2020. | 0.3   | \$ 350 | \$<br>105.00   |
| Frankie Angeleri | 07/08/20 | (0.6) Continue, from same day, to review and concurrently create a list of the relevant materials, data and information from the KPMG share site.  | 0.6   | \$ 520 | \$<br>312.00   |
| Rob Keller       | 07/08/20 | (0.8) Conference call with T. Stone and R. Keller (KPMG) to further discuss/refine analysis regarding certain tax deductions.  | 0.8   | \$ 893 | \$<br>714.40   |
| Tracy Stone      | 07/08/20 | (0.8) Conference call with T. Stone and R. Keller (KPMG) to further discuss/refine analysis regarding certain tax deductions.  | 0.8   | \$ 906 | \$<br>724.80   |
| Becky Holtje     | 07/08/20 | (1.0) Perform research, as of 7/8/2020, to facilitate cash tax modeling regarding timing of certain deductions for taxpayers.  | 1.0   | \$ 744 | \$<br>744.00   |
| Jess Commisso    | 07/08/20 | (1.6) Review of most recent documentation provided by client as of 7/8/2020, to determine relevance (and distribution of same) to various KPMG project teams - to facilitate tax analysis.   | 1.6   | \$ 350 | \$<br>560.00   |
| Isaac Hirsch     | 07/08/20 | (2.1) Performed Managing Director review of updated Dutch disposition planning slides as of 7/8/2020.  | 2.1   | \$ 819 | \$<br>1,719.90 |
| Devon Rowles     | 07/08/20 | (2.1) Updating the document listing tracker to include information received in the virtual data room (VDR) as of 7-8-2020.   | 2.1   | \$ 350 | \$<br>735.00   |
| Ashley Armfield  | 07/08/20 | (1.3) Reviewing 2013 US tax filings pursuant to gain insight into client history; (1.1) Drafted summary of key findings of US tax filings to progress tax analysis.  | 2.4   | \$ 534 | \$<br>1,281.60 |
| Isaac Hirsch     | 07/08/20 | (3.3) International Managing Director level analysis of US partnership tax returns for purposes of testing assumptions in cash tax model   | 3.3   | \$ 819 | \$<br>2,702.70 |
| Frankie Angeleri | 07/08/20 | (3.9) Continued (from previous day) to address review comments from K. Taylor (KPMG) related to transfer pricing memo.   | 3.9   | \$ 520 | \$<br>2,028.00 |
| Frankie Angeleri | 07/08/20 | (3.9) Review and concurrently create a list of the relevant materials, data and information from the KPMG share site.  | 3.9   | \$ 520 | \$<br>2,028.00 |
| Devon Rowles     | 07/08/20 | (3.9) Performed a detailed review of documents received as of 7/8/2020 in order to notify the wider KPMG US Core team about relevant tax documents received.   | 3.9   | \$ 350 | \$<br>1,365.00 |
| Tracy Stone      | 07/09/20 | (0.3) Performed Principal WNT analysis of origin of the claim case law in connection with fraudulent conveyance analysis.  | 0.3   | \$ 906 | \$<br>271.80   |
| Tracy Stone      | 07/09/20 | (0.5) Principal WNT review of Purdue ownership structure in connection with fraudulent conveyance analysis.  | 0.5   | \$ 906 | \$<br>453.00   |

### Purdue Pharma L.P. Case No. 19-23649

| Name         | Date     | Description   | Hours | Rate   | Amount       |
|--------------|----------|---|-------|--------|--------------|
| Tracy Stone  | 07/09/20 | (0.5) Performed Principal WNT review of trust characteristics in connection with fraudulent conveyance analysis.  | 0.5   | \$ 906 | \$<br>453.00 |
| Tracy Stone  | 07/09/20 | (0.7) Perform Principal WNT Review Purdue term sheet in connection with direct liability analysis.  | 0.7   | \$ 906 | \$<br>634.20 |
| Isaac Hirsch | 07/09/20 | (0.8) Perform Managing director review of updated Canadian disposition planning slides as of $7/9/2020.$  | 0.8   | \$ 819 | \$<br>655.20 |
| Becky Holtje | 07/09/20 | Discussion with J. Tod (US National Tax expert on Passthroughs), B. Unell (US National expert on Restructuring), T. Stone (US National Tax expert on Trusts) - partial attendance, R. Keller (US National Tax expert on Passthroughs) - partial attendance, B. Holtje (US National Tax - Restructuring Specialist) - partial attendance, I. Hirsch, C. Nunez and P. DiMatteo (KPMG) regarding various issues relating to distributions made by Purdue and certain tax deductions. | 1.0   | \$ 744 | \$<br>744.00 |
| Rob Keller   | 07/09/20 | Discussion with J. Tod (US National Tax expert on Passthroughs), B. Unell (US National expert on Restructuring), T. Stone (US National Tax expert on Trusts) - partial attendance, R. Keller (US National Tax expert on Passthroughs) - partial attendance, B. Holtje (US National Tax - Restructuring Specialist) - partial attendance, I. Hirsch, C. Nunez and P. DiMatteo (KPMG) regarding various issues relating to distributions made by Purdue and certain tax deductions. | 1.0   | \$ 893 | \$<br>893.00 |
| Tracy Stone  | 07/09/20 | Discussion with J. Tod (US National Tax expert on Passthroughs), B. Unell (US National expert on Restructuring), T. Stone (US National Tax expert on Trusts) - partial attendance, R. Keller (US National Tax expert on Passthroughs) - partial attendance, B. Holtje (US National Tax - Restructuring Specialist) - partial attendance, I. Hirsch, C. Nunez and P. DiMatteo (KPMG) regarding various issues relating to distributions made by Purdue and certain tax deductions. | 1.0   | \$ 906 | \$<br>906.00 |
| Bela Unell   | 07/09/20 | Discussion with J. Tod (US National Tax expert on Passthroughs), B. Unell (US National expert on Restructuring), T. Stone (US National Tax expert on Trusts) - partial attendance, R. Keller (US National Tax expert on Passthroughs) - partial attendance, B. Holtje (US National Tax - Restructuring Specialist) - partial attendance, I. Hirsch, C. Nunez and P. DiMatteo (KPMG) regarding various issues relating to distributions made by Purdue and certain tax deductions. | 1.1   | \$ 744 | \$<br>818.40 |
| Casey Nunez  | 07/09/20 | Discussion with J. Tod (US National Tax expert on Passthroughs), B. Unell (US National expert on Restructuring), T. Stone (US National Tax expert on Trusts) - partial attendance, R. Keller (US National Tax expert on Passthroughs) - partial attendance, B. Holtje (US National Tax - Restructuring Specialist) - partial attendance, I. Hirsch, C. Nunez and P. DiMatteo (KPMG) regarding various issues relating to distributions made by Purdue and certain tax deductions. | 1.1   | \$ 744 | \$<br>818.40 |

### Purdue Pharma L.P. Case No. 19-23649

| Name             | Date     | Description   | Hours | Rate   | Amount         |
|------------------|----------|---|-------|--------|----------------|
| Isaac Hirsch     | 07/09/20 | Discussion with J. Tod (US National Tax expert on Passthroughs), B. Unell (US National expert on Restructuring), T. Stone (US National Tax expert on Trusts) - partial attendance, R. Keller (US National Tax expert on Passthroughs) - partial attendance, B. Holtje (US National Tax - Restructuring Specialist) - partial attendance, I. Hirsch, C. Nunez and P. DiMatteo (KPMG) regarding various issues relating to distributions made by Purdue and certain tax deductions. | 1.1   | \$ 819 | \$<br>900.90   |
| Jim Tod          | 07/09/20 | Discussion with J. Tod (US National Tax expert on Passthroughs), B. Unell (US National expert on Restructuring), T. Stone (US National Tax expert on Trusts) - partial attendance, R. Keller (US National Tax expert on Passthroughs) - partial attendance, B. Holtje (US National Tax - Restructuring Specialist) - partial attendance, I. Hirsch, C. Nunez and P. DiMatteo (KPMG) regarding various issues relating to distributions made by Purdue and certain tax deductions. | 1.1   | \$ 906 | \$<br>996.60   |
| Pete DiMatteo    | 07/09/20 | Discussion with J. Tod (US National Tax expert on Passthroughs), B. Unell (US National expert on Restructuring), T. Stone (US National Tax expert on Trusts) - partial attendance, R. Keller (US National Tax expert on Passthroughs) - partial attendance, B. Holtje (US National Tax - Restructuring Specialist) - partial attendance, I. Hirsch, C. Nunez and P. DiMatteo (KPMG) regarding various issues relating to distributions made by Purdue and certain tax deductions. | 1.1   | \$ 650 | \$<br>715.00   |
| Rob Keller       | 07/09/20 | (1.5) Performed analysis related to results of discussion with broader KPMG team regarding Purdue trusts.   | 1.5   | \$ 893 | \$<br>1,339.50 |
| Tracy Stone      | 07/09/20 | (1.5) Analysis of certain timing considerations for tax deductions.   | 1.5   | \$ 906 | \$<br>1,359.00 |
| Isaac Hirsch     | 07/09/20 | (1.8) Analysis of cash tax model assumptions for testing of same by review of tax return information.   | 1.8   | \$ 819 | \$<br>1,474.20 |
| Ashley Armfield  | 07/09/20 | (1.8) Reviewing updated information request list with regards to new information received as of 7/9/2020.   | 1.8   | \$ 534 | \$<br>961.20   |
| Pete DiMatteo    | 07/09/20 | (1.9) Perform international tax manager review of assumptions made with respect to global cash tax model against tax return information provided as of 7/9/2020.  | 1.9   | \$ 650 | \$<br>1,235.00 |
| Devon Rowles     | 07/09/20 | (1.9) Updates to the Purdue cash tax model with regards to review comments received from senior associate (A. Armfield) as of 7/9/2020.   | 1.9   | \$ 350 | \$<br>665.00   |
| Gabriela Baker   | 07/09/20 | (2.0) Review of US tax filings for two US partnerships.   | 2.0   | \$ 534 | \$<br>1,068.00 |
| Frankie Angeleri | 07/09/20 | (2.0) Creating transaction flow of all entities, including their intercompany transactions.   | 2.0   | \$ 520 | \$<br>1,040.00 |
| Pete DiMatteo    | 07/09/20 | (2.1) Perform international tax manager review of US tax filings for US partnership.  | 2.1   | \$ 650 | \$<br>1,365.00 |
| Jess Commisso    | 07/09/20 | (2.3) Continue, same day, to review US tax filings provided by client to analyze what information can be incorporated into our cash tax model and to see which US tax filings are still outstanding.  | 2.3   | \$ 350 | \$<br>805.00   |

#### Purdue Pharma L.P. Case No. 19-23649

| Name              | Date     | Description  | Hours | Rate   | Amount         |
|-------------------|----------|--|-------|--------|----------------|
| Isaac Hirsch      | 07/09/20 | (2.3) Performed analysis of US partnership tax returns for purposes of testing assumptions in cash tax model   | 2.3   | \$ 819 | \$<br>1,883.70 |
| Ashley Armfield   | 07/09/20 | (1.3) Review of 2017 US partnership tax filing to gaining insight into client history, (1.2) Review of 2018 US partnership tax filing pursuant to gaining insight into client history.   | 2.5   | \$ 534 | \$<br>1,335.00 |
| Ashley Armfield   | 07/09/20 | (1.1) Review of 2014 US tax filing to gaining insight into client history, (1.4) Review of 2015 US tax filing pursuant to gaining insight into client history, (0.9) Review of 2016 US tax filing pursuant to gaining insight into client history. | 3.4   | \$ 534 | \$<br>1,815.60 |
| Jess Commisso     | 07/09/20 | (3.9) Review of US tax filings provided by client to analyze what information can be incorporated into our cash tax model / which US tax filings are still outstanding.  | 3.9   | \$ 350 | \$<br>1,365.00 |
| Frankie Angeleri  | 07/10/20 | Meeting with M. Minnear (KPMG), K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss the preliminary draft and structure of KPMG's internal transfer pricing summary memo as well as next steps.   | 0.3   | \$ 520 | \$<br>156.00   |
| Kieran Taylor     | 07/10/20 | Meeting with M. Minnear (KPMG), K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss the preliminary draft and structure of KPMG's internal transfer pricing summary memo as well as next steps.   | 0.3   | \$ 744 | \$<br>223.20   |
| Molly Minnear     | 07/10/20 | Meeting with M. Minnear (KPMG), K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss the preliminary draft and structure of KPMG's internal transfer pricing summary memo as well as next steps.   | 0.3   | \$ 868 | \$<br>260.40   |
| Anthony Minervini | 07/10/20 | Discussion with J. Tod and A. Minervini (both KPMG) regarding research related to certain tax deductions.  | 0.5   | \$ 893 | \$<br>446.50   |
| Jim Tod           | 07/10/20 | Discussion with J. Tod and A. Minervini (both KPMG) regarding research related to certain tax deductions.  | 0.5   | \$ 906 | \$<br>453.00   |
| Howard Steinberg  | 07/10/20 | Performed Partner review of updated assumptions included in latest Purdue tax analysis with regards to Mundipharma disposition.  | 1.0   | \$ 856 | \$<br>856.00   |
| Isaac Hirsch      | 07/10/20 | (1.2) Managing director review of analysis of plan for testing cash tax modeling assumptions using tax return information.   | 1.2   | \$ 819 | \$<br>982.80   |
| Jess Commisso     | 07/10/20 | Updates to the Purdue cash tax model with regards to review comments received from A. Armfield (KPMG).   | 2.4   | \$ 350 | \$<br>840.00   |
| Pete DiMatteo     | 07/10/20 | (2.6) Performed additional international tax manager review of global cash tax model assumptions against tax return information provided this week.  | 2.6   | \$ 650 | \$<br>1,690.00 |
| Isaac Hirsch      | 07/10/20 | (2.6) Performed Managing director review of updated cash tax model as of 7/10/2020.  | 2.6   | \$ 819 | \$<br>2,129.40 |
| Devon Rowles      | 07/10/20 | (2.8) Updating the cash tax model with regards to senior associate (A. Armfield) review comments received as of 6/10/2020.   | 2.8   | \$ 350 | \$<br>980.00   |

### Purdue Pharma L.P. Case No. 19-23649

| Name              | Date     | Description  | Hours | Rate   | Amount         |
|-------------------|----------|--|-------|--------|----------------|
| Diego Lipp        | 07/13/20 | Review of new Swiss documents uploaded to the virtual data room as of 7/13/2020 and simultaneously draft e-mail to D. Rowles (KPMG US) regarding relevant key findings.  | 0.3   | \$ 430 | \$<br>129.00   |
| Anthony Minervini | 07/13/20 | Additional meeting with J. Tod (KPMG) to discuss research related to certain tax deductions.   | 0.6   | \$ 893 | \$<br>535.80   |
| Jim Tod           | 07/13/20 | Additional meeting with A. Minervini (KPMG) to discuss research related to certain tax deductions.   | 0.6   | \$ 906 | \$<br>543.60   |
| Pete DiMatteo     | 07/13/20 | Continued, same day, to perform international tax manager review of assumptions related to global cash tax model (0.4). Begin draft of additional information requests for information necessary to test assumptions (0.8)   | 1.2   | \$ 650 | \$<br>780.00   |
| Devon Rowles      | 07/13/20 | 1.4 Performed a detailed review of client tax documents received as of 7-13-2020 in order to notify the wider KPMG US team about relevant tax documents received that could impact various disposition scenarios in the cash tax model   | 1.4   | \$ 350 | \$<br>490.00   |
| Kieran Taylor     | 07/13/20 | Collated transfer pricing summary schedule used to document Purdue's existing transfer pricing arrangements.   | 1.8   | \$ 744 | \$<br>1,339.20 |
| Casey Nunez       | 07/13/20 | (2.3) Performed M&A Tax Senior Manager review of updated cash tax model assumptions for purposes of identifying any potentially material gaps in missing information   | 2.3   | \$ 744 | \$<br>1,711.20 |
| Rob Keller        | 07/13/20 | Performed research, as discussed with A. Minervini (KPMG), related to certain tax deductions.  | 2.3   | \$ 893 | \$<br>2,053.90 |
| Pete DiMatteo     | 07/13/20 | International tax manager review of assumptions related to global cash tax model (1.4). Begin to draft additional information requests for information necessary to test assumptions (1.2).  | 2.6   | \$ 650 | \$<br>1,690.00 |
| Isaac Hirsch      | 07/13/20 | (2.2) Managing director review of updates to cash tax cost model; (0.9) perform managing director review of Dutch tax planning for purposes of determining potential cash tax effect of proposed transactions; (0.8) performed managing director review of schedule of potential overall foreign loss accounts for purposes of updating cash tax model with same | 3.9   | \$ 819 | \$<br>3,194.10 |
| Anthony Minervini | 07/13/20 | Per request from J. Tod (KPMG), performed research relating to certain tax deductions.   | 2.9   | \$ 893 | \$<br>2,589.70 |
| Anthony Minervini | 07/13/20 | Per request from J. Tod (KPMG), performed additional research relating to certain tax deductions.  | 2.3   | \$ 893 | \$<br>2,053.90 |
| Anthony Minervini | 07/13/20 | Per request from J. Tod (KPMG), continued from same day, to perform additional research relating to certain tax deductions.  | 1.8   | \$ 893 | \$<br>1,607.40 |
| Anthony Minervini | 07/13/20 | Drafting summary of research and analysis performed relating to certain tax deductions.  | 0.7   | \$ 893 | \$<br>625.10   |
| Jonas Lau         | 07/14/20 | Drafted email response to KPMG US questions regarding potential Canadian tax planning for the potential disposition of Canadian entity.  | 0.4   | \$ 614 | \$<br>245.60   |

#### Purdue Pharma L.P. Case No. 19-23649

| Name               | Date     | Description  | Hours | Rate   | Amount         |
|--------------------|----------|--|-------|--------|----------------|
| Gabriela Baker     | 07/14/20 | Call with P. DiMatteo and G. Baker (both KPMG) to discuss the Partnership Undistributed Income Analysis for Purdue foreign entities.   | 0.6   | \$ 534 | \$<br>320.40   |
| Pete DiMatteo      | 07/14/20 | Call with P. DiMatteo and G. Baker (both KPMG) to discuss the Partnership Undistributed Income Analysis for Purdue foreign entities.   | 0.6   | \$ 650 | \$<br>390.00   |
| Gabriela Baker     | 07/14/20 | Call with P. DiMatteo and G. Baker (both KPMG) to discuss background of Purdue entities related to Partnership Undistributed Income Analysis.  | 1.4   | \$ 534 | \$<br>747.60   |
| Pete DiMatteo      | 07/14/20 | Call with P. DiMatteo and G. Baker (both KPMG) to discuss background of Purdue entities related to Partnership Undistributed Income Analysis.  | 1.4   | \$ 650 | \$<br>910.00   |
| Gabriela Baker     | 07/14/20 | Perform partnership undistributed income analysis for Purdue domestic partnership and foreign trusts.  | 1.3   | \$ 534 | \$<br>694.20   |
| Jess Commisso      | 07/14/20 | 1.8 Review of US tax filings provided by client, as of 7/14/2020, to determine which US tax filings are still outstanding that are needed to further analyze our trust analysis.   | 1.8   | \$ 350 | \$<br>630.00   |
| Pete DiMatteo      | 07/14/20 | 2.7 Performed international tax manager review of various tax filings of certain Purdue entities in an effort to test assumptions made with respect to the global cash tax model.  | 2.7   | \$ 650 | \$<br>1,755.00 |
| Anthony Minervini  | 07/14/20 | Continue from 7/13/20, drafting summary of research and analysis performed relating to certain tax deductions.   | 2.7   | \$ 893 | \$<br>2,411.10 |
| Isaac Hirsch       | 07/14/20 | (2.4) Updates to cash tax model to include potential effects of overall foreign loss accounts for purposes of determining the cash tax effects of same   | 2.4   | \$ 819 | \$<br>1,965.60 |
| Lukas van der Veen | 07/15/20 | Review the potential impact of a legislative proposal on the potential disposition of Dutch entities, specifically with respect to dividend withholding tax.   | 0.9   | \$ 565 | \$<br>508.50   |
| Lukas van der Veen | 07/15/20 | Draft e-mail to KPMG US on the potential impact of a legislative proposal on the potential disposition of Dutch entities, specifically with respect to dividend withholding tax.   | 1.0   | \$ 565 | \$<br>565.00   |
| Aroen Rambhadjan   | 07/15/20 | Partner review and concurrent updating of e-mail drafted by L. van der Veen (KPMG Netherlands) regarding the potential impact of a legislative proposal on the potential disposition of Dutch entities, specifically with respect to dividend withholding tax.     | 0.8   | \$ 884 | \$<br>707.20   |
| Jim Tod            | 07/15/20 | Partner review of research relating to certain tax deductions.   | 0.6   | \$ 906 | \$<br>543.60   |
| Pete DiMatteo      | 07/15/20 | 0.8 Perform international tax manager review of research prepared by KPMG professionals relating to certain tax deductions.  | 0.8   | \$ 650 | \$<br>520.00   |
| Gabriela Baker     | 07/15/20 | 0.9 Phone conference between P. DiMatteo and G. Baker (both KPMG) to discuss the Purdue's partnerships' undistributed income analysis and additional information request in order to obtain additional information required for basis analysis of non-US entities. | 0.9   | \$ 534 | \$<br>480.60   |

### Purdue Pharma L.P. Case No. 19-23649

| Name               | Date     | Description  | Hours | Rate   | Amount         |
|--------------------|----------|--|-------|--------|----------------|
| Pete DiMatteo      | 07/15/20 | 0.9 Phone conference between P. DiMatteo and G. Baker (both KPMG) to discuss the Purdue's partnerships' undistributed income analysis and additional information request in order to obtain additional information required for basis analysis of non-US entities. | 0.9   | \$ 650 | \$<br>585.00   |
| Pete DiMatteo      | 07/15/20 | 1.1 Performed international tax manager review of information received and drafting of request of additional information for purposes of testing assumptions made in connection with the global cash tax model.  | 1.1   | \$ 650 | \$<br>715.00   |
| Howard Steinberg   | 07/15/20 | Partner review of updated information request list as provided by I. Hirsch (KPMG) for cash tax modeling assumption testing.   | 1.5   | \$ 856 | \$<br>1,284.00 |
| Gabriela Baker     | 07/15/20 | Performed Partnership Undistributed Income Analysis for foreign entities.  | 1.7   | \$ 534 | \$<br>907.80   |
| Isaac Hirsch       | 07/15/20 | (1.2) Performed managing director review of updated information request list for cash tax model assumption testing; (0.8) managing director review of Washington National Tax analysis for purposes of including same in cash tax model                            | 2.0   | \$ 819 | \$<br>1,638.00 |
| Kieran Taylor      | 07/15/20 | Revision of transfer pricing analysis pursuant to receipt of transfer pricing reports as of 7/15/2020.   | 2.1   | \$ 744 | \$<br>1,562.40 |
| Frankie Angeleri   | 07/15/20 | 2.6 Reviewing transfer pricing reports on the share site.  | 2.6   | \$ 520 | \$<br>1,352.00 |
| Lukas van der Veen | 07/16/20 | (Continued from previous day) Finalize draft e-mail on the potential impact of a legislative proposal on the potential disposition of Dutch entities, specifically with respect to dividend withholding tax.   | 0.2   | \$ 565 | \$<br>113.00   |
| Lukas van der Veen | 07/16/20 | Draft follow-up email response to P. DiMatteo (KPMG US) regarding the potential impact of legislative proposal on the Dutch dividend withholding tax.  | 0.5   | \$ 565 | \$<br>282.50   |
| Isaac Hirsch       | 07/16/20 | 0.9 Conference call between I. Hirsch, P. DiMatteo, J. Commisso, and D. Rowles (all KPMG) to discuss the Purdue cash tax model assumptions, specifically related to the value allocation of each disposition entity  | 0.9   | \$ 819 | \$<br>737.10   |
| Pete DiMatteo      | 07/16/20 | 0.9 Conference call between I. Hirsch, P. DiMatteo, J. Commisso, and D. Rowles (all KPMG) to discuss the Purdue cash tax model assumptions, specifically related to the value allocation of each disposition entity  | 0.9   | \$ 650 | \$<br>585.00   |
| Devon Rowles       | 07/16/20 | 0.9 Conference call between I. Hirsch, P. DiMatteo, J. Commisso, and D. Rowles (all KPMG) to discuss the Purdue cash tax model assumptions, specifically related to the value allocation of each disposition entity  | 0.9   | \$ 350 | \$<br>315.00   |
| Jess Commisso      | 07/16/20 | 0.9 Conference call between I. Hirsch, P. DiMatteo, J. Commisso, and D. Rowles (all KPMG) to discuss the Purdue cash tax model assumptions, specifically related to the value allocation of each disposition entity  | 0.9   | \$ 350 | \$<br>315.00   |
| Pete DiMatteo      | 07/16/20 | 1.6 Perform international tax manager review of proposed Dutch planning in light of recent Dutch tax legislative proposals.  | 1.6   | \$ 650 | \$<br>1,040.00 |

#### Purdue Pharma L.P. Case No. 19-23649

| Name             | Date     | Description  | Hours | Rate   | Amount         |
|------------------|----------|--|-------|--------|----------------|
| Jess Commisso    | 07/16/20 | 1.6 Performed analysis of tax filings and financial statements of subsidiaries of disposition entities to determine additional tax exposure.   | 1.6   | \$ 350 | \$<br>560.00   |
| Pete DiMatteo    | 07/16/20 | 2.2 Review proposed transactions in connection with testing certain assumptions made for purposes of the global cash tax model;  | 2.2   | \$ 650 | \$<br>1,430.00 |
| Frankie Angeleri | 07/16/20 | Reviewing transfer pricing report documentation provided by client.  | 2.8   | \$ 520 | \$<br>1,456.00 |
| Devon Rowles     | 07/16/20 | 3.1 Performed a detailed review of tax documentation received as of 7-16-2020 in order to notify the wider KPMG team about relevant tax documents received.  | 3.1   | \$ 350 | \$<br>1,085.00 |
| Isaac Hirsch     | 07/16/20 | (3.1) Additional updates to cash tax model to include potential effects of overall foreign loss accounts for purposes of determining the cash tax effects of same; (0.8) performed analysis of potential effects on cash tax modeling of allocations of value to lower-tier subsidiaries | 3.9   | \$ 819 | \$<br>3,194.10 |
| Frankie Angeleri | 07/17/20 | Call between K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss the approach to the profit and loss model for all Purdue entities.   | 0.1   | \$ 520 | \$<br>52.00    |
| Kieran Taylor    | 07/17/20 | Call between K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss the approach to the profit and loss model for all Purdue entities.   | 0.1   | \$ 744 | \$<br>74.40    |
| Frankie Angeleri | 07/17/20 | 0.6 Review of information on the information provided by client, as of 7/1/2020; 0.6 Adding additional information to transfer pricing preliminary draft memo to organize functions / transfer pricing policies of the entities.   | 1.2   | \$ 520 | \$<br>624.00   |
| Gabriela Baker   | 07/17/20 | Performed Partnership Undistributed Income Analysis for various entities to determine potential undistributed losses.  | 1.3   | \$ 534 | \$<br>694.20   |
| Casey Nunez      | 07/17/20 | Testing of assumptions in cash tax model to evaluate potential for material differences in results   | 1.6   | \$ 744 | \$<br>1,190.40 |
| Pete DiMatteo    | 07/17/20 | 2.9 Performed international tax manager review of information provided (e.g., local tax returns and financial statements) to test various assumptions made in connection with global cash tax model;   | 2.9   | \$ 650 | \$<br>1,885.00 |
| Jess Commisso    | 07/17/20 | 3.2 Performed analysis of tax filings / financial statements of subsidiaries of disposition entities to determine additional tax exposure.   | 3.2   | \$ 350 | \$<br>1,120.00 |
| Isaac Hirsch     | 07/20/20 | (0.6) Perform managing director review of updates to Dutch tax planning slides with respect to new proposed Dutch legislation  | 0.6   | \$ 819 | \$<br>491.40   |
| Ashley Armfield  | 07/20/20 | 0.7 Meeting with A. Armfield and D. Rowles (KPMG) to discuss updates that need to be made to Purdue cash tax modeling with regards to the inclusion of overall foreign losses.   | 0.7   | \$ 534 | \$<br>373.80   |
| Devon Rowles     | 07/20/20 | 0.7 Meeting with A. Armfield and D. Rowles (KPMG) to discuss updates that need to be made to Purdue cash tax modeling with regards to the inclusion of overall foreign losses.   | 0.7   | \$ 350 | \$<br>245.00   |
| Pete DiMatteo    | 07/20/20 | 1.2 Perform international tax manager review of relevant structures for purposes of determine potential effects of valuation changes;  | 1.2   | \$ 650 | \$<br>780.00   |

#### Purdue Pharma L.P. Case No. 19-23649

| Name               | Date     | Description  | Hours | Rate   | Amount         |
|--------------------|----------|--|-------|--------|----------------|
| Jess Commisso      | 07/20/20 | Continued, from earlier in the day, to perform analysis of tax filings / financial statements of subsidiaries of disposition entities.   | 1.2   | \$ 350 | \$<br>420.00   |
| Becky Holtje       | 07/20/20 | 1.5 Performed research, as of 7/20, to facilitate cash tax modeling regarding timing of certain deductions.  | 1.5   | \$ 744 | \$<br>1,116.00 |
| Devon Rowles       | 07/20/20 | 2.9 Updating Purdue cash tax model with regards to review comments received from KPMG managing director (I. Hirsch) as of 7/20/2020.   | 2.9   | \$ 350 | \$<br>1,015.00 |
| Ashley Armfield    | 07/20/20 | 0.6 Review of managing director (I. Hirsch) comments relating to cash tax modeling and the inclusion of overall foreign losses. 2.8 Senior Associate review of updated cash tax model provided by staff relating to updates for overall foreign loss inclusions. | 3.4   | \$ 534 | \$<br>1,815.60 |
| Gabriela Baker     | 07/20/20 | Began to perform analysis as well as related calculations of certain income of foreign entities.   | 3.9   | \$ 534 | \$<br>2,082.60 |
| Gabriela Baker     | 07/20/20 | Continue, same day, to perform analysis as well as related calculations of certain income of foreign entities.   | 1.6   | \$ 534 | \$<br>854.40   |
| Aroen Rambhadjan   | 07/20/20 | Partner review of draft e-mail for KPMG US prepared by L. van der<br>Veen (KPMG Netherlands) regarding potential Dutch tax planning for<br>potential disposition of Dutch entities.  | 0.3   | \$ 884 | \$<br>265.20   |
| Lukas van der Veen | 07/20/20 | Draft follow-up e-mail for KPMG US regarding potential tax planning for the potential disposition of Dutch entities.   | 0.5   | \$ 565 | \$<br>282.50   |
| Lukas van der Veen | 07/21/20 | Follow-up draft e-mail response to I. Hirsch (KPMG US) regarding potential tax planning for the potential disposition of Dutch entities.   | 0.5   | \$ 565 | \$<br>282.50   |
| Aroen Rambhadjan   | 07/21/20 | Partner review of draft follow-up e-mail prepared by L. van der Veen (KPMG Netherlands) sent to I. Hirsch (KPMG US). E-mail related to potential Dutch tax planning.   | 0.1   | \$ 884 | \$<br>88.40    |
| Pete DiMatteo      | 07/21/20 | Performed International tax manager review (0.2) and related correspondence to KPMG UK tax team (0.4) regarding relevant structures for purposes of determine potential effects of valuation changes;  | 0.6   | \$ 650 | \$<br>390.00   |
| Kieran Taylor      | 07/21/20 | Review of Purdue transfer pricing.   | 1.4   | \$ 744 | \$<br>1,041.60 |
| Casey Nunez        | 07/21/20 | (1.8) Perform M&A Tax Senior Manager review of analysis of potential tax deductions.   | 1.8   | \$ 744 | \$<br>1,339.20 |
| Ashley Armfield    | 07/21/20 | 2.3 Review of ownership structure of Purdue entities in order to provide information to KPMG partnership tax specialists.  | 2.3   | \$ 534 | \$<br>1,228.20 |
| Jess Commisso      | 07/21/20 | 3.2 Analysis of partners of Purdue entities to support determination of allowable deductions.  | 3.2   | \$ 350 | \$<br>1,120.00 |
| Isaac Hirsch       | 07/21/20 | (3.1) Performed managing director review of updates to cash tax model to incorporate overall foreign loss account effect.  | 3.1   | \$ 819 | \$<br>2,538.90 |
| Isaac Hirsch       | 07/21/20 | (0.9) Performed Managing director review of analysis of value push-<br>down to lower tier subsidiaries for purposes of cash tax modeling; (0.7)<br>performed analysis related to certain potential deductions.   | 1.6   | \$ 819 | \$<br>1,310.40 |

### Purdue Pharma L.P. Case No. 19-23649

| Name             | Date     | Description  | Hours | Rate   | Amount         |
|------------------|----------|--|-------|--------|----------------|
| Frankie Angeleri | 07/22/20 | 0.2 Meeting with K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss progress on Profit and Loss model, preliminary draft transfer pricing memo and next steps as of 7/22/2020.   | 0.2   | \$ 520 | \$<br>104.00   |
| Kieran Taylor    | 07/22/20 | 0.2 Meeting with K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss progress on Profit and Loss model, preliminary draft transfer pricing memo and next steps as of 7/22/2020.   | 0.2   | \$ 744 | \$<br>148.80   |
| Gabriela Baker   | 07/22/20 | Phone conference between P. DiMatteo and G. Baker (both KPMG) to discuss the undistributed earnings analysis of certain foreign trusts.  | 0.5   | \$ 534 | \$<br>267.00   |
| Pete DiMatteo    | 07/22/20 | Phone conference between P. DiMatteo and G. Baker (both KPMG) to discuss the undistributed earnings analysis of certain foreign trusts.  | 0.5   | \$ 650 | \$<br>325.00   |
| Bela Unell       | 07/22/20 | (.6) Performed WNT Director review of technical summaries to be provided to income tax accounting experts in anticipation of technical call.   | 0.6   | \$ 744 | \$<br>446.40   |
| Douglas Holland  | 07/22/20 | Perform WNT review of tax comments as well as revisions to client deliverable planning alternatives structure deck.  | 1.0   | \$ 985 | \$<br>985.00   |
| Molly Minnear    | 07/22/20 | Performed Principal Economic and Valuation Services review of draft<br>deliverables prepared by team to prepare for upcoming discussion on<br>next steps in analysis.  | 1.2   | \$ 868 | \$<br>1,041.60 |
| Frankie Angeleri | 07/22/20 | 1.7 Updating preliminary transfer pricing draft memo based on results of discussion with K. Taylor (KPMG).   | 1.7   | \$ 520 | \$<br>884.00   |
| Casey Nunez      | 07/22/20 | (1.9) Performed M&A Tax Senior Manager review of updates to cash tax model to reflect overall foreign loss of Purdue   | 1.9   | \$ 744 | \$<br>1,413.60 |
| Ashley Armfield  | 07/22/20 | Updating Purdue cash tax modeling for comments from managing director I. Hirsch (KPMG) relating to overall foreign loss inclusions.  | 2.1   | \$ 534 | \$<br>1,121.40 |
| Isaac Hirsch     | 07/22/20 | (2.3) Performed additional managing director review of updates to cash tax model to incorporate overall foreign loss account effect  | 2.3   | \$ 819 | \$<br>1,883.70 |
| Frankie Angeleri | 07/22/20 | 0.2 Review of profit and loss file provided by client; 1.3 Creating list of relevant provided by client documentation to our transfer pricing analysis to determine what information we have / what information we have outstanding; 0.7 Reviewing transfer pricing report; 0.7 Reviewing transfer pricing reports in preparation to add information to preliminary draft memo for transfer pricing. | 2.9   | \$ 520 | \$<br>1,508.00 |
| Casey Nunez      | 07/22/20 | (2.7) Performed M&A Tax Senior Manager review of updates to cash tax model to reflect new scenarios without certain tax deductions to perform sensitivity analysis for uncertainty in law changes  | 2.7   | \$ 744 | \$<br>2,008.80 |
| Devon Rowles     | 07/22/20 | 3.9 Updating the cash tax model with regards to managing director (I. Hirsch) review comments received as of 7/22/2020.  | 3.9   | \$ 350 | \$<br>1,365.00 |

### Purdue Pharma L.P. Case No. 19-23649

| Name             | Date     | Description   | Hours | Rate   | Amount         |
|------------------|----------|---|-------|--------|----------------|
| Pete DiMatteo    | 07/23/20 | (0.3) Meeting between I. Hirsh, P. DiMatteo and G. Baker (all KPMG) to determine additional information required for analysis of certain foreign trusts.                      | 0.3   | \$ 650 | \$<br>195.00   |
| Gabriela Baker   | 07/23/20 | (0.3) Meeting between I. Hirsh, P. DiMatteo and G. Baker (all KPMG) to determine additional information required for analysis of certain foreign trusts.                      | 0.3   | \$ 534 | \$<br>160.20   |
| Isaac Hirsch     | 07/23/20 | (0.3) Meeting between I. Hirsh, P. DiMatteo and G. Baker (all KPMG) to determine additional information required for analysis of certain foreign trusts.                      | 0.3   | \$ 819 | \$<br>245.70   |
| Becky Holtje     | 07/23/20 | 0.3 Perform research, as of 7/23/2020, to facilitate cash tax modeling regarding timing of certain deductions.  | 0.3   | \$ 744 | \$<br>223.20   |
| Jess Commisso    | 07/23/20 | 1.7 Review of documentation provided by client, as of $7/23$ , with regards to relevance to tax engagement - in preparation to share with KPMG tax team professionals.        | 1.7   | \$ 350 | \$<br>595.00   |
| Devon Rowles     | 07/23/20 | 2.1 Performed a detailed review of documents received as of 7-23-2020 in order to notify the wider KPMG US team about relevant tax documents received.                        | 2.1   | \$ 350 | \$<br>735.00   |
| Pete DiMatteo    | 07/23/20 | 2.3 International tax manager review and concurrently revised alternate planning structure deck deliverable.  | 2.3   | \$ 650 | \$<br>1,495.00 |
| Casey Nunez      | 07/23/20 | (2.9) Perform M&A Tax Senior Manager Review of planning deck for disposition structuring opportunities  | 2.9   | \$ 744 | \$<br>2,157.60 |
| Frankie Angeleri | 07/24/20 | Meeting with M. Minnear (KPMG), K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss the progress of the preliminary draft transfer pricing memo and the profit and loss model. | 0.2   | \$ 520 | \$<br>104.00   |
| Kieran Taylor    | 07/24/20 | Meeting with M. Minnear (KPMG), K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss the progress of the preliminary draft transfer pricing memo and the profit and loss model. | 0.2   | \$ 744 | \$<br>148.80   |
| Molly Minnear    | 07/24/20 | Meeting with M. Minnear (KPMG), K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss the progress of the preliminary draft transfer pricing memo and the profit and loss model. | 0.2   | \$ 868 | \$<br>173.60   |
| Isaac Hirsch     | 07/24/20 | (0.8) Performed analysis of potential partnership tax consequences of proposed Dutch tax planning transactions  | 0.8   | \$ 819 | \$<br>655.20   |
| Rob Keller       | 07/26/20 | 3.5 Performed analysis in connection with potential tax deductions as well as next steps.   | 3.5   | \$ 893 | \$<br>3,125.50 |
| Becky Holtje     | 07/27/20 | Analysis conducted in connection with potential tax deductions as well as next steps.   | 0.4   | \$ 744 | \$<br>297.60   |

### Purdue Pharma L.P. Case No. 19-23649

| Name            | Date     | Description   | Hours | Rate   | Amount    |
|-----------------|----------|---|-------|--------|-----------|
| Carol Conjura   | 07/27/20 | R. Holtje (US National Tax - Restructuring Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), B. Unell (US National Tax - Restructuring Specialist), T. Stone (US National Tax - Trust Specialist), R. Keller (Passthrough Specialist), C. Conjura (Income tax accounting specialist) - partial attendance, P. DiMatteo (Core Engagement Team - US International Tax), A. Armfield (Core Engagement Team - US M&A Tax) met for discussion of research conducted in connection with potential tax deductions as well as next steps. | 0.5   | \$ 906 | \$ 453.00 |
| Ashley Armfield | 07/27/20 | R. Holtje (US National Tax - Restructuring Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), B. Unell (US National Tax - Restructuring Specialist), T. Stone (US National Tax - Trust Specialist), R. Keller (Passthrough Specialist), C. Conjura (Income tax accounting specialist) - partial attendance, P. DiMatteo (Core Engagement Team - US International Tax), A. Armfield (Core Engagement Team - US M&A Tax) met for discussion of research conducted in connection with potential tax deductions as well as next steps. | 1.1   | \$ 534 | \$ 587.40 |
| Becky Holtje    | 07/27/20 | R. Holtje (US National Tax - Restructuring Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), B. Unell (US National Tax - Restructuring Specialist), T. Stone (US National Tax - Trust Specialist), R. Keller (Passthrough Specialist), C. Conjura (Income tax accounting specialist) - partial attendance, P. DiMatteo (Core Engagement Team - US International Tax), A. Armfield (Core Engagement Team - US M&A Tax) met for discussion of research conducted in connection with potential tax deductions as well as next steps. | 1.1   | \$ 744 | \$ 818.40 |
| Bela Unell      | 07/27/20 | R. Holtje (US National Tax - Restructuring Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), B. Unell (US National Tax - Restructuring Specialist), T. Stone (US National Tax - Trust Specialist), R. Keller (Passthrough Specialist), C. Conjura (Income tax accounting specialist) - partial attendance, P. DiMatteo (Core Engagement Team - US International Tax), A. Armfield (Core Engagement Team - US M&A Tax) met for discussion of research conducted in connection with potential tax deductions as well as next steps. | 1.1   | \$ 744 | \$ 818.40 |
| Casey Nunez     | 07/27/20 | R. Holtje (US National Tax - Restructuring Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), B. Unell (US National Tax - Restructuring Specialist), T. Stone (US National Tax - Trust Specialist), R. Keller (Passthrough Specialist), C. Conjura (Income tax accounting specialist) - partial attendance, P. DiMatteo (Core Engagement Team - US International Tax), A. Armfield (Core Engagement Team - US M&A Tax) met for discussion of research conducted in connection with potential tax deductions as well as next steps. | 1.1   | \$ 744 | \$ 818.40 |

### Purdue Pharma L.P. Case No. 19-23649

| Name           | Date     | Description   | Hours | Rate   | Amount         |
|----------------|----------|---|-------|--------|----------------|
| Isaac Hirsch   | 07/27/20 | R. Holtje (US National Tax - Restructuring Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), B. Unell (US National Tax - Restructuring Specialist), T. Stone (US National Tax - Trust Specialist), R. Keller (Passthrough Specialist), C. Conjura (Income tax accounting specialist) - partial attendance, P. DiMatteo (Core Engagement Team - US International Tax), A. Armfield (Core Engagement Team - US M&A Tax) met for discussion of research conducted in connection with potential tax deductions as well as next steps. | 1.1   | \$ 819 | \$<br>900.90   |
| Pete DiMatteo  | 07/27/20 | R. Holtje (US National Tax - Restructuring Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), B. Unell (US National Tax - Restructuring Specialist), T. Stone (US National Tax - Trust Specialist), R. Keller (Passthrough Specialist), C. Conjura (Income tax accounting specialist) - partial attendance, P. DiMatteo (Core Engagement Team - US International Tax), A. Armfield (Core Engagement Team - US M&A Tax) met for discussion of research conducted in connection with potential tax deductions as well as next steps. | 1.1   | \$ 650 | \$<br>715.00   |
| Rob Keller     | 07/27/20 | R. Holtje (US National Tax - Restructuring Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), B. Unell (US National Tax - Restructuring Specialist), T. Stone (US National Tax - Trust Specialist), R. Keller (Passthrough Specialist), C. Conjura (Income tax accounting specialist) - partial attendance, P. DiMatteo (Core Engagement Team - US International Tax), A. Armfield (Core Engagement Team - US M&A Tax) met for discussion of research conducted in connection with potential tax deductions as well as next steps. | 1.1   | \$ 893 | \$<br>982.30   |
| Tracy Stone    |          | R. Holtje (US National Tax - Restructuring Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), B. Unell (US National Tax - Restructuring Specialist), T. Stone (US National Tax - Trust Specialist), R. Keller (Passthrough Specialist), C. Conjura (Income tax accounting specialist) - partial attendance, P. DiMatteo (Core Engagement Team - US International Tax), A. Armfield (Core Engagement Team - US M&A Tax) met for discussion of research conducted in connection with potential tax deductions as well as next steps. | 1.1   | \$ 906 | \$<br>996.60   |
| Isaac Hirsch   | 07/27/20 | (1.4) Perform managing director review of updates to Dutch planning proposal to incorporate additional guidance form KPMG Netherlands   | 1.4   | \$ 819 | \$<br>1,146.60 |
| Tracy Stone    | 07/27/20 | 0.5 Consideration related to deductibility of payment by trust beneficiaries; 0.5 discussion via email with R. Keller KPMG) related to same; 0.5 performed analysis related to treatment of various attributes at trust termination;  | 1.5   | \$ 906 | \$<br>1,359.00 |
| Gabriela Baker | 07/27/20 | Draft of Information Request List (IRL) with respect to Partnership Undistributed Income Capital Account Analysis.  | 2.1   | \$ 534 | \$<br>1,121.40 |

### Purdue Pharma L.P. Case No. 19-23649

| Name              | Date     | Description   | Hours | Rate   | Amount         |
|-------------------|----------|---|-------|--------|----------------|
| Isaac Hirsch      | 07/27/20 | (2.8) Managing director review of additional changes to cash tax model to incorporate estimated effect of overall foreign loss account  | 2.8   | \$ 819 | \$<br>2,293.20 |
| Frankie Angeleri  | 07/27/20 | 3.5 Began to create Profit & Loss model and concurrently performing related calculations based on transfer pricing policies.  | 3.5   | \$ 520 | \$<br>1,820.00 |
| Jim Tod           | 07/28/20 | (0.3) Reviewing prior notes related to potential U.S. tax implications of proposed Dutch/Canadian transactions in order to prepare for call with KPMG team later in the day.  | 0.3   | \$ 906 | \$<br>271.80   |
| Anthony Minervini | 07/28/20 | (0.7) Discussion with J. Tod (US National Tax - Partnership Specialist), A. Minervini (US National Tax - Partnership Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), and P. DiMatteo (Core Engagement Team - US International Tax) regarding potential U.S. tax implications of proposed Dutch/Canadian transactions as well as next steps; | 0.7   | \$ 893 | \$<br>625.10   |
| Casey Nunez       | 07/28/20 | (0.7) Discussion with J. Tod (US National Tax - Partnership Specialist), A. Minervini (US National Tax - Partnership Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), and P. DiMatteo (Core Engagement Team - US International Tax) regarding potential U.S. tax implications of proposed Dutch/Canadian transactions as well as next steps  | 0.7   | \$ 744 | \$<br>520.80   |
| Isaac Hirsch      | 07/28/20 | (0.7) Discussion with J. Tod (US National Tax - Partnership Specialist), A. Minervini (US National Tax - Partnership Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), and P. DiMatteo (Core Engagement Team - US International Tax) regarding potential U.S. tax implications of proposed Dutch/Canadian transactions as well as next steps  | 0.7   | \$ 819 | \$<br>573.30   |
| Jim Tod           | 07/28/20 | (0.7) Discussion with J. Tod (US National Tax - Partnership Specialist), A. Minervini (US National Tax - Partnership Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), and P. DiMatteo (Core Engagement Team - US International Tax) regarding potential U.S. tax implications of proposed Dutch/Canadian transactions as well as next steps; | 0.7   | \$ 906 | \$<br>634.20   |
| Pete DiMatteo     | 07/28/20 | (0.7) Discussion with J. Tod (US National Tax - Partnership Specialist), A. Minervini (US National Tax - Partnership Specialist), C. Nunez (Core Engagement Team - US M&A Tax), I. Hirsch (Core Engagement Team - US International Tax), and P. DiMatteo (Core Engagement Team - US International Tax) regarding potential U.S. tax implications of proposed Dutch/Canadian transactions as well as next steps. | 0.7   | \$ 650 | \$<br>455.00   |

### Purdue Pharma L.P. Case No. 19-23649

| Name              | Date     | Description  | Hours | Rate   | Amount         |
|-------------------|----------|--|-------|--------|----------------|
| Frankie Angeleri  | 07/28/20 | Continued (on same day) to create Profit & Loss model and concurrently performing related calculations based on transfer pricing policies.   | 0.7   | \$ 520 | \$<br>364.00   |
| Rob Keller        | 07/28/20 | 0.8 Performed research in connection with potential tax deductions, as well as next steps.   | 0.8   | \$ 893 | \$<br>714.40   |
| Isaac Hirsch      | 07/28/20 | (0.8) Perform managing director review of additional analysis of US federal income tax consequences of proposed Dutch disposition planning   | 0.8   | \$ 819 | \$<br>655.20   |
| Anthony Minervini | 07/28/20 | Per request from P. DiMatteo (KPMG), reviewed and concurrently commented on partnership tax considerations for Netherlands planning in draft step plan.  | 1.0   | \$ 893 | \$<br>893.00   |
| Jess Commisso     | 07/28/20 | 1.4 Creation of information request list pursuant to undistributed earnings analysis of foreign trusts.  | 1.4   | \$ 350 | \$<br>490.00   |
| Howard Steinberg  | 07/28/20 | Performed Partner review of client deliverables regarding tax analysis of Mundipharma disposition.   | 1.5   | \$ 856 | \$<br>1,284.00 |
| Pete DiMatteo     | 07/28/20 | 1.9 Perform international tax manager review and concurrently updated information request listing regarding testing of certain assumptions related to global cash tax model.                     | 1.9   | \$ 650 | \$<br>1,235.00 |
| Casey Nunez       | 07/28/20 | (1.9) Performed M&A Tax Senior Manager review of updates to cash tax model for application of Purdue foreign tax credit profile.   | 1.9   | \$ 744 | \$<br>1,413.60 |
| Isaac Hirsch      | 07/28/20 | (2.2) Performed managing director review of additional updates to cash tax model to implement summary of effect of overall foreign loss account on cash taxes                                    | 2.2   | \$ 819 | \$<br>1,801.80 |
| Frankie Angeleri  | 07/28/20 | 3.9 Continued from 7/27 to create Profit & Loss model and concurrently performing related calculations based on transfer pricing policies.   | 3.9   | \$ 520 | \$<br>2,028.00 |
| Tracy Stone       | 07/29/20 | Performed WNT research over law regarding tax benefit rule and trust distributions related to Purdue Pharma.   | 0.5   | \$ 906 | \$<br>453.00   |
| Ashley Armfield   | 07/29/20 | 0.9 Reviewed new guidelines released pertaining to certain tax elections.  | 0.9   | \$ 534 | \$<br>480.60   |
| Rob Keller        | 07/29/20 | 1.0 Continued, from 7/28, to perform research in connection with potential tax deductions, as well as next steps.  | 1.0   | \$ 893 | \$<br>893.00   |
| Frankie Angeleri  | 07/29/20 | Continued from 7/28 to create Profit & Loss model and concurrently performing related calculations based on transfer pricing policies.   | 1.5   | \$ 520 | \$<br>780.00   |
| Howard Steinberg  | 07/29/20 | (1.6) Perform Partner review of client deliverables, as of 7/29/2020, regarding tax analysis of Mundipharma disposition.   | 1.6   | \$ 856 | \$<br>1,369.60 |
| Mark Hoffenberg   | 07/29/20 | Performed WNT review of update on Overall foreign loss (OFL) and Dutch/Canadian planning issues (0.6), and review of latest version of the Dutch/Canada planning deck with regards to same (1.0) | 1.6   | \$ 980 | \$<br>1,568.00 |

### Purdue Pharma L.P. Case No. 19-23649

| Name              | Date     | Description  | Hours | Rate   | Amount         |
|-------------------|----------|--|-------|--------|----------------|
| Isaac Hirsch      | 07/29/20 | (1.1) Performed managing director review of additional updates to cash tax model to implement summary of effect of overall foreign loss account on cash taxes; (0.6) performed analysis of US federal income tax consequences of proposed Dutch disposition planning   | 1.7   | \$ 819 | \$<br>1,392.30 |
| Pete DiMatteo     | 07/29/20 | 2.1 Performed international tax manager updates to information request listing regarding testing of certain assumptions related to global cash tax model.  | 2.1   | \$ 650 | \$<br>1,365.00 |
| Casey Nunez       | 07/29/20 | (1.3) Performed M&A Tax Senior Manager review of new information request list to evaluate tax basis and undistributed income. (2.1) M&A Tax Senior Manager review of updates to cash tax model for reflecting prior foreign losses of various entities.  | 3.4   | \$ 744 | \$<br>2,529.60 |
| Frankie Angeleri  | 07/30/20 | Meeting with K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss findings, questions and next steps with regard to transfer pricing.  | 0.4   | \$ 520 | \$<br>208.00   |
| Kieran Taylor     | 07/30/20 | Meeting with K. Taylor (KPMG) and F. Angeleri (KPMG) to discuss findings, questions and next steps with regard to transfer pricing.  | 0.4   | \$ 744 | \$<br>297.60   |
| Douglas Holland   | 07/30/20 | 0.6 Telephone conference with D. Holland (US National Office - International Tax Specialist), I. Hirsch (Core Engagement Team - International Tax), and P. DiMatteo (Core Engagement Team - International Tax) (all KPMG) to discuss potential planning with respect to contemplated Dutch transactions and updates to global cash tax model | 0.6   | \$ 985 | \$<br>591.00   |
| Isaac Hirsch      | 07/30/20 | 0.6 Telephone conference with D. Holland (US National Office - International Tax Specialist), I. Hirsch (Core Engagement Team - International Tax), and P. DiMatteo (Core Engagement Team - International Tax) (all KPMG) to discuss potential planning with respect to contemplated Dutch transactions and updates to global cash tax model | 0.6   | \$ 819 | \$<br>491.40   |
| Pete DiMatteo     | 07/30/20 | 0.6 Telephone conference with D. Holland (US National Office - International Tax Specialist), I. Hirsch (Core Engagement Team - International Tax), and P. DiMatteo (Core Engagement Team - International Tax) (all KPMG) to discuss potential planning with respect to contemplated Dutch transactions and updates to global cash tax model | 0.6   | \$ 650 | \$<br>390.00   |
| Tracy Stone       | 07/30/20 | Continued, same day, to perform research relating to various legal theories associated with payments to the Purdue settlement vehicle.   | 0.6   | \$ 906 | \$<br>543.60   |
| Anthony Minervini | 07/30/20 | J. Tod (US National Tax - Pass-through Specialist), A. Minervini (US National Tax - Pass-through Specialist), R. Keller (US National Tax - Pass-through Specialist), discussion of research conducted in connection with certain potential tax deductions as well as next steps.   | 0.8   | \$ 893 | \$<br>714.40   |
| Jim Tod           | 07/30/20 | J. Tod (US National Tax - Pass-through Specialist), A. Minervini (US National Tax - Pass-through Specialist), R. Keller (US National Tax - Pass-through Specialist), discussion of research conducted in connection with certain potential tax deductions as well as next steps.   | 0.8   | \$ 906 | \$<br>724.80   |

### Purdue Pharma L.P. Case No. 19-23649

| Name              | Date     | Description  | Hours | Rate   | Amount           |
|-------------------|----------|--|-------|--------|------------------|
| Rob Keller        | 07/30/20 | J. Tod (US National Tax - Pass-through Specialist), A. Minervini (US National Tax - Pass-through Specialist), R. Keller (US National Tax - Pass-through Specialist), discussion of research conducted in connection with certain potential tax deductions as well as next steps.     | 0.8   | \$ 893 | \$<br>714.40     |
| Rob Keller        | 07/30/20 | 1.0 T. Stone (US National Tax - Trust Specialist) and R. Keller (Pass-through Specialist) met for discussion of research conducted in connection with payments (and corresponding deductibility of such payments) that will be made to the settlement vehicle as well as next steps. | 1.0   | \$ 893 | \$<br>893.00     |
| Tracy Stone       | 07/30/20 | 1.0 T. Stone (US National Tax - Trust Specialist) and R. Keller (Pass-through Specialist) met for discussion of research conducted in connection with payments (and corresponding deductibility of such payments) that will be made to the settlement vehicle as well as next steps. | 1.0   | \$ 906 | \$<br>906.00     |
| Jess Commisso     | 07/30/20 | 1.8 Creation of information request list for analysis of undistributed income and basis of Mundipharma entities.   | 1.8   | \$ 350 | \$<br>630.00     |
| Frankie Angeleri  | 07/30/20 | Creating summary of the financial profit and loss model for 2017 $(1.0)$ , 2018 $(0.7)$ , and 2019 $(0.6)$ .   | 2.3   | \$ 520 | \$<br>1,196.00   |
| Isaac Hirsch      | 07/30/20 | (3.4) Updates to cash tax model to incorporate recently-released regulations regarding the global intangible low-taxed income high-tax exception   | 3.4   | \$ 819 | \$<br>2,784.60   |
| Tracy Stone       | 07/30/20 | Prepared summary of research relating to various legal theories associated with payments to the Purdue settlement vehicle.   | 3.9   | \$ 906 | \$<br>3,533.40   |
| Douglas Holland   | 07/31/20 | 0.5 Performed Principal WNT review of tax implications, set forth in PowerPoint proposal, of Dutch and Canadian tax planning opportunities   | 0.5   | \$ 985 | \$<br>492.50     |
| Isaac Hirsch      | 07/31/20 | (0.6) Analysis of US federal income tax effects of income distributed from partnership for purposes of cash tax modeling.  | 0.6   | \$ 819 | \$<br>491.40     |
| Pete DiMatteo     | 07/31/20 | 1.6 Performed international tax manager review of 2013-2018 US tax return filings for a US partnership to gain insight regarding the entity's historical tax profile.  | 1.6   | \$ 650 | \$<br>1,040.00   |
| Becky Holtje      | 07/31/20 | 1.7 Performed research, as of 7/31/2020, to facilitate cash tax modeling regarding timing of certain deductions.   | 1.7   | \$ 744 | \$<br>1,264.80   |
| Anthony Minervini | 07/31/20 | Review and concurrently comment on partnership tax considerations for Canada planning in draft step plan.  | 2.0   | \$ 893 | \$<br>1,786.00   |
| Frankie Angeleri  | 07/31/20 | 2.1 Continued, from $7/30,$ creating summary of the financial profit and loss model for 2017, 2018, and 2019.  | 2.1   | \$ 520 | \$<br>1,092.00   |
|                   |          | <b>Total Bankruptcy Tax Consulting Services</b>  | 349.0 |        | \$<br>229,296.10 |

# 19-23649-rdd Doc 1655 Filed 09/03/20 Entered 09/03/20 22:40:42 Main Document Pg 24 of 29

### EXHIBIT C2

#### Purdue Pharma L.P. Case No. 19-23649

Non -Working Travel Time July 1, 2020 through July 31, 2020

| Name | Date | Description  | Hours | Rate | Amount |
|------|------|--|-------|------|--------|
|      |      | no fees billed for these services in current month |       |      |        |
|      |      | Total Non-Working Travel Time                      |       |      | \$ -   |

# 19-23649-rdd Doc 1655 Filed 09/03/20 Entered 09/03/20 22:40:42 Main Document Pg 25 of 29

### **EXHIBIT C3**

Purdue Pharma L.P.
Case No. 19-23649
Retention Services
July 1, 2020 through July 31, 2020

| Name | Date | Description                                       | Hours | Rate | Amount |
|------|------|---|-------|------|--------|
|      | n    | o fees billed for these services in current month |       |      |        |
|      |      | <b>Total Retention Services</b>                   | 0.0   |      | \$ -   |

#### Purdue Pharma L.P. Case No. 19-23649

Fee Application Preparation Services July 1, 2020 through July 31, 2020

| Name            | Date     | Description  | Hours | Rate   | A  | Amount |
|-----------------|----------|--|-------|--------|----|--------|
| Wendy Shaffer   | 07/02/20 | 0.7 Updated Purdue 5th monthly fee statement per direction from Davis Polk, re-PDF and send for filing.  | 0.7   | \$ 202 | \$ | 141.40 |
| Wendy Shaffer   | 07/07/20 | 0.3 Prepared Purdue May file in Excel for the fee examiner and send to M. Plangman (KPMG) for approval of same   | 0.3   | \$ 202 | \$ | 60.60  |
| Monica Plangman | 07/07/20 | (0.1) Review of Fee Examiner report and (0.1) send to W. Shaffer (KPMG).   | 0.2   | \$ 264 | \$ | 52.80  |
| Wendy Shaffer   | 07/08/20 | 0.1 Drafted email to B. Masumoto (US Trustee) to provide copy of KPMG's 5th monthly fee statement in the Purdue Pharma matter in both PDF and Excel format.  | 0.1   | \$ 202 | \$ | 20.20  |
| Wendy Shaffer   | 07/13/20 | 0.3 Updated to Purdue June monthly fee statement to include additional data received from professionals as of 7/13/2020  | 0.3   | \$ 202 | \$ | 60.60  |
| Monica Plangman | 07/14/20 | Performed Associate director initial review of interim documents and provide comments.   | 0.5   | \$ 264 | \$ | 132.00 |
| Monica Plangman | 07/15/20 | Fee statement review of documents, as of 7/15/20, and concurrently provide comments.   | 2.7   | \$ 264 | \$ | 712.80 |
| Wendy Shaffer   | 07/15/20 | 1.9 Updates to Purdue Pharma 2nd Interim statement per review comments received from M. Plangman (KPMG); 0.1 email to H. Steinberg (KPMG) to request approval of Purdue Pharma 2nd Interim fee statement; 0.2 PDF Purdue Pharma 2nd Interim statement and 0.1 send to M. Plangman (KPMG) for final review/approval before sending to counsel for filing; 0.1 Updates to exhibit C1 of Purdue June monthly fee statement to include data received from professionals as of 7/15/2020; 0.1 email to M. Pera (Davis Polk) to request filing/services of KPMG's 2nd Interim fee statement; 0.2 Review work in progress report for Purdue for July to confirm billable hours from 7/1 - 7/14; | 2.6   | \$ 202 | \$ | 525.20 |
| Teresa Williams | 07/15/20 | Updated assigned portion of exhibit C1 of Purdue Pharma July monthly fee statement to include data received from professionals as of 7/15/2020   | 2.4   | \$ 140 | \$ | 336.00 |
| Teresa Williams | 07/16/20 | Update assigned portion of exhibit C1 of Purdue Pharma July monthly fee statement to include data received from professionals as of 7/16/2021  | 0.7   | \$ 140 | \$ | 98.00  |
| Wendy Shaffer   | 07/16/20 | 1.0 Updated exhibit C1 of Purdue June monthly fee statement to include data received from professionals as of 7/16/2020.   | 1.0   | \$ 202 | \$ | 202.00 |
| Wendy Shaffer   | 07/19/20 | 0.9 Updated exhibit C1 of Purdue June monthly fee statement to include data received from professionals as of 7/20/2020 and 0.1 send June file to M. Land (KPMG) to request updates to monthly fee statement with regards to previous comments from Davis Polk   | 1.0   | \$ 202 | \$ | 202.00 |
| Wendy Shaffer   | 07/20/20 | 0.1 Communication with M. Land (KPMG) regarding updates requested to Purdue June fee statement.  | 0.1   | \$ 202 | \$ | 20.20  |
| Wendy Shaffer   | 07/21/20 | 1.0 Updated Purdue Pharma July monthly fee statement per direction from M. Land (KPMG) and 0.1 drafted email to send final draft to M. Plangman (KPMG) for Associate Director review.  | 1.1   | \$ 202 | \$ | 222.20 |

### Purdue Pharma L.P. Case No. 19-23649

Fee Application Preparation Services July 1, 2020 through July 31, 2020

| Name            | Date     | Description  | Hours | Rate   | Amount      |
|-----------------|----------|--|-------|--------|-------------|
| Wendy Shaffer   | 07/22/20 | 0.1 Updates to Purdue June monthly fee statement to incorporate KPMG foreign member time detail received as of 7/22/2020 and 0.1 send email to M. Plangman (KPMG) to provide updated draft of June fee statement for review.   | 0.2   | \$ 202 | \$ 40.40    |
| Monica Plangman | 07/27/20 | Performed Associate director review of fee statement and concurrently provide comments.  | 1.5   | \$ 264 | \$ 396.00   |
| Wendy Shaffer   | 07/28/20 | 0.6 Updates to exhibit C1 of Purdue July monthly fee statement to include data received from professionals as of 7/29/2020; 0.6 Updates to Purdue 6th monthly per review comments from M. Plangman (KPMG); 0.1 send copy of finalized exhibits to Partners/team leads to request approval of same;   | 1.3   | \$ 202 | \$ 262.60   |
| Casey Nunez     | 07/30/20 | Performed Senior Manager review of Purdue June monthly fee statement<br>and concurrently drafted review comments to provide to W. Shaffer<br>(KPMG)  | 1.5   | \$ 744 | \$ 1,116.00 |
| Wendy Shaffer   | 07/30/20 | 0.3 Updated Purdue Pharma 6th monthly fee statement per direction from A. Armfield (KPMG) and updated Purdue cover sheet with regards to same; 0.1 drafted email to send copy of final drafts to M. Plangman (KPMG) for approval prior to sending to partner for sign-off; 0.1 drafted email to H. Steinberg KPMG) to request approval / permission to apply electronic signature to final drafts of Purdue 6th monthly fee statement. | 0.5   | \$ 202 | \$ 101.00   |
| Wendy Shaffer   | 07/31/20 | 0.2 Finalized (PDF) Purdue June monthly fee statement in preparation for filing and 0.1 draft email to M. Plangman (KPMG) to request approval of same prior to sending to counsel for filing/service; 0.1 drafted email to Davis Polk to request filing and services of Purdue 6th monthly fee statement;  | 0.4   | \$ 202 | \$ 80.80    |
|                 |          | <b>Total Fee Application Preparation Services</b>  | 19.1  |        | \$ 4,782.80 |

### **EXHIBIT D**

### Purdue Pharma L.P. Case No. 19-23649

Summary of Out of Pocket Expenses July 1, 2020 through July 31, 2020

| Category              | Amo  | unt |
|-----------------------|------|-----|
| Airfare               | \$   | -   |
| Lodging               | \$   | -   |
| Meals                 | \$   | -   |
| Ground Transportation | \$   | -   |
| Miscellaneous         | _ \$ | -   |
| Total                 | \$   | -   |

# 19-23649-rdd Doc 1655 Filed 09/03/20 Entered 09/03/20 22:40:42 Main Document Pg 29 of 29

### EXHIBIT D1

### Purdue Pharma L.P. Case No. 19-23649

Detail of Out of Pocket Expenses July 1, 2020 through July 31, 2020

| Name | Date | Description                        | Amount |
|------|------|------------------------------------|--------|
|      |      | Air Fare Subtotal                  | \$ -   |
|      |      | Lodging Subtotal                   | \$ -   |
|      |      | Meals Subtotal                     | \$ -   |
|      |      | <b>Total Ground Transportation</b> | \$ -   |
|      |      | Miscellaneous Subtotal             | \$ -   |
|      |      | Total Out of Pocket Expenses       | \$ -   |